coronavirida
envelop
nonseg
singlestrand
positivesens
rna
virus
name
coronaor
crownlik
surfac
project
seen
electron
microscopi
correspond
larg
surfac
spike
protein
figur
coronavirus
hostspecif
infect
human
well
varieti
differ
anim
caus
divers
clinic
syndrom
three
serolog
genet
distinct
group
coronavirus
describ
human
coronavirus
hcov
part
group
primarili
caus
varieti
respiratori
tract
infect
tabl
coronavirus
recogn
diseas
agent
anim
thirti
year
later
coronavirus
identifi
agent
respiratori
tract
infect
human
first
recogn
hcov
includ
less
well
recogn
strain
also
describ
investig
date
littl
known
regard
preval
associ
clinic
ill
coronaviruslik
particl
also
detect
stool
possibl
enter
pathogen
primarili
infant
gastroenter
necrot
enterocol
character
possibl
virus
cultur
specimen
dramat
sever
acut
respiratori
syndrom
sar
cov
identifi
novel
respiratori
pathogen
respons
global
outbreak
sar
outbreak
last
month
ultim
result
peopl
infect
death
expert
believ
sarscov
evolv
natur
reservoir
sarscovlik
virus
horsesho
bat
civet
cat
serv
intermedi
host
find
novel
hcov
initi
renew
interest
cov
research
year
later
refer
variou
public
nl
nh
identifi
newli
recogn
hcov
sinc
shown
present
human
respiratori
sampl
earli
relat
hcov
origin
describ
enter
coronaviruslik
particl
detect
stool
unclear
hcov
sarscov
found
worldwid
caus
diseas
predominantli
winter
spring
month
temper
climat
seropreval
data
suggest
exposur
common
earli
childhood
approxim
adult
seroposit
sarscov
hand
identifi
sinc
decemb
sporad
case
sar
associ
transmiss
identifi
china
communityacquir
case
laboratoryacquir
sar
isol
case
cluster
case
death
refer
avail
onlin
wwwexpertconsultcom
nasal
congest
sore
throat
sneez
cough
may
associ
fever
togeth
next
common
caus
common
cold
rhinovirus
base
data
symptom
typic
peak
day
ill
selflimit
hcov
also
may
associ
acut
otiti
media
exacerb
asthma
less
frequent
virus
associ
lower
respiratori
tract
infect
includ
bronchiol
pneumonia
primarili
infant
immunocompromis
children
adult
compar
hcov
frequent
associ
croup
next
common
isol
parainfluenza
viru
type
possibl
associ
kawasaki
diseas
substanti
associ
symptom
gastroenter
includ
vomit
diarrhea
typic
occur
along
respiratori
symptom
also
appear
frequent
associ
febril
seizur
compar
hcov
compar
hcov
sarscov
associ
sever
symptom
sarscov
disproportion
affect
adult
typic
manifest
fever
myalgia
headach
malais
chill
follow
nonproduct
cough
dyspnea
day
later
approxim
develop
wateri
diarrhea
respiratori
distress
progress
requir
intub
ventil
case
overal
associ
mortal
rate
approxim
death
occur
third
week
ill
casefat
rate
person
age
approach
typic
laboratori
abnorm
includ
lymphopenia
increas
serum
lactat
dehydrogenas
creatin
kinas
level
major
progress
unilater
bilater
illdefin
airspac
infiltr
chest
imag
pneumothorac
sign
barotrauma
common
critic
ill
patient
receiv
mechan
ventil
infant
children
appear
protect
sarscov
infect
clinic
manifest
infect
children
less
sever
notabl
infant
children
die
due
sarscov
infect
outbreak
infant
children
year
age
develop
sar
typic
manifest
fever
cough
rhinorrhea
associ
lymphopenia
less
sever
radiograph
chang
milder
gener
resolv
quickli
adolesc
adult
adolesc
develop
sar
clinic
cours
close
resembl
adult
manifest
fever
myalgia
headach
chill
adolesc
like
develop
dyspnea
hypoxemia
worsen
chest
radiograph
find
laboratori
abnorm
compar
adult
women
infect
sarscov
pregnanc
surviv
increas
risk
spontan
miscarriag
preterm
deliveri
intrauterin
growth
restrict
two
neonat
born
mother
sar
outbreak
develop
gastrointestin
complic
jejun
perfor
necrot
enterocol
ileal
perfor
shortli
birth
neither
clinic
evid
sarscov
infect
unclear
whether
find
relat
complic
matern
sarscov
infect
treatment
use
pregnanc
ribavirin
corticosteroid
past
diagnosi
infect
due
hcov
typic
attempt
clinic
set
outsid
outbreak
situat
epidemiolog
survey
howev
sar
outbreak
renew
interest
identifi
etiolog
respiratori
tract
infect
special
laboratori
offer
comprehens
diagnost
test
respiratori
tract
specimen
primarili
base
rtpcr
panel
includ
detect
hcov
antibodi
test
also
avail
sarscov
upper
lower
respiratori
tract
specimen
appropri
sampl
viral
detect
test
avail
stool
sampl
frequent
posit
patient
sar
posit
children
infect
serum
sampl
may
posit
identifi
southeast
asia
relat
breach
biosafeti
practic
differ
laboratori
cultiv
sarscov
mode
transmiss
hcov
sarscov
well
studi
howev
base
studi
respiratori
virus
like
transmiss
occur
primarili
via
combin
droplet
direct
indirect
contact
spread
mode
import
remain
determin
possibl
role
aerosol
spread
need
studi
droplet
direct
contact
spread
like
common
mode
transmiss
sarscov
although
evid
indirect
contact
spread
aerosol
spread
also
exist
evid
vertic
transmiss
sarscov
base
data
hcov
sarscov
like
transmit
first
day
ill
symptom
viral
load
respiratori
tract
highest
studi
need
confirm
also
case
recent
identifi
sarscov
hand
like
transmit
second
week
ill
symptom
viral
load
respiratori
tract
peak
incub
period
day
median
day
studi
need
confirm
incub
period
nonsarshcov
incub
period
sarscov
day
median
day
pathogenesi
hcov
best
describ
sarscov
sarscov
evid
infect
adult
given
children
affect
outbreak
studi
need
understand
pathogenesi
hcov
infect
initi
inocul
mucos
surfac
respiratori
tract
infect
associ
nasal
mucos
plasma
exud
increas
level
nasal
lavag
specimen
correl
symptom
sever
viral
load
respiratori
tract
specimen
peak
within
first
day
infect
drop
dramat
week
correl
develop
subsequ
improv
symptom
antibodi
detect
start
week
correl
drop
viral
load
reach
maximum
level
approxim
week
later
thereaft
antibodi
titer
declin
slowli
immun
complet
reinfect
common
higher
circul
antibodi
level
especi
level
specif
iga
antihcov
correl
reduc
viru
shed
reduc
symptom
upon
reexposur
sarscov
infect
like
initi
inocul
respiratori
tract
mucosa
subsequ
viremia
follow
predomin
replic
lung
gastrointestin
tract
replic
site
also
like
occur
given
wide
distribut
sarscov
tissu
examin
autopsi
peak
viral
load
nasopharyng
specimen
note
second
week
symptom
rise
sarscov
specif
antibodi
typic
seen
start
week
infect
increas
antibodi
titer
symptomat
improv
second
third
week
associ
fall
quantiti
sarscov
measur
revers
transcriptas
polymeras
chain
reaction
rtpcr
paradox
despit
fall
sarscov
viral
load
rise
sarsspecif
antibodi
clinic
deterior
observ
patient
suggest
host
immun
respons
like
respons
clinic
deterior
inde
sar
associ
elev
inflammatori
cytokin
interleukin
il
well
elev
neutrophil
chemokin
monocyt
chemoattract
protein
level
correl
sever
diseas
hcov
associ
common
cold
acut
otiti
media
asthma
exacerb
less
frequent
bronchiol
pneumonia
also
associ
croup
also
associ
vomit
diarrhea
frequent
respiratori
tract
symptom
appear
associ
frequent
febril
seizur
compar
hcov
sarscov
associ
sar
attend
mortal
rate
primarili
affect
adult
adolesc
children
year
age
develop
sar
typic
less
sever
manifest
fever
cough
rhinorrhea
upper
lower
respiratori
tract
specimen
test
hcov
rtpcr
stool
sampl
frequent
posit
patient
sarscov
posit
children
infect
antibodi
test
also
avail
sarscov
hcov
support
care
sarscov
definit
treatment
recommend
lack
control
trial
patient
sarscov
specimen
like
posit
first
day
ill
whether
also
true
need
studi
sarscov
serum
sampl
rtpcr
test
like
posit
first
week
ill
respiratori
stool
specimen
may
posit
second
week
ill
symptom
viral
load
peak
compar
adult
infant
children
sarscov
infect
less
like
posit
specimen
consist
milder
symptom
presum
correspondingli
lower
viral
load
children
laboratori
guidanc
sarscov
diagnost
test
avail
center
diseas
control
prevent
websit
given
potenti
falseposit
result
associ
public
health
implic
test
sarscov
absenc
known
persontoperson
transmiss
sarscov
done
caution
prefer
consult
region
public
health
depart
high
degre
clinic
suspicion
altern
diagnosi
mild
symptom
selflimit
natur
hcov
infect
sarscov
treatment
studi
perform
gener
care
support
sarscov
infect
seriou
corticosteroid
type
ifn
agent
convalesc
plasma
ribavirin
lopinavirritonavir
use
treat
sar
treatment
anecdot
report
suggest
benefit
vitro
assay
anim
model
support
despit
report
anecdot
clinic
improv
ribavirin
howev
vitro
studi
support
like
efficaci
sinc
sar
outbreak
agent
test
vitro
appear
promis
includ
viral
entri
proteas
inhibit
agent
rna
interf
agent
glycyrrhizin
howev
definit
conclus
drawn
regard
efficaci
treatment
noteworthi
control
studi
perform
agent
report
unev
recoveri
patient
given
support
care
alon
event
sarscov
reemerg
clarif
effect
treatment
control
clinic
trial
need
meticul
hand
respiratori
hygien
use
easili
implement
control
measur
curb
spread
respiratori
virus
includ
hcov
prevent
measur
assess
prophylact
intranas
shown
reduc
durat
sever
infect
research
set
use
clinic
studi
prevent
hcov
proprietari
extract
root
north
american
ginseng
panax
quinquefolium
shown
reduc
number
cold
well
sever
durat
cold
symptom
adult
taken
daili
presum
due
immun
stimul
efficaci
decreas
cold
specif
due
hcov
studi
healthcar
personnel
wear
mask
evalu
person
cough
ill
use
gown
glove
mask
eye
protect
durat
ill
care
children
hospit
sign
symptom
respiratori
tract
infect
precaut
replac
mask
respir
avail
plu
negativepressur
isol
recommend
patient
sarscov
infect
durat
ill
day
resolut
fever
provid
respiratori
symptom
absent
improv
clean
disinfect
environment
surfac
frequent
touch
infect
person
use
standard
disinfect
decreas
potenti
indirect
transmiss
hcov
via
fomit
control
sar
outbreak
credit
rapid
identif
case
earli
implement
infect
control
public
health
measur
includ
contact
trace
quarantin
sarscov
reemerg
measur
implement
quickli
attempt
prevent
recurr
worldwid
outbreak
